Nature Biotechnology, published online: May 29, 2025; DOI: 10.1038 / S41587-025-02683-Z
The bankruptcy of 23andme serves as a moment of reflection on the direct genomic industry to consumers (DTC). We have analyzed financial data and financial practices of 23andme to reveal the factors behind the fall in the company, once evaluated at $ 6 billion and now being considered for the acquisition by Regeneron for only $ 250 million. The main challenges encountered by 23andme to monetize his genomic data reveal that this information, at least in a typical DTC parameter, simply not worth as much.
